However, recent results indicate that in fact the opposite may be true [20], [21], [22], so that it is presently unclear to which extent activation of the AKT pathway can explain the poor prognosis associated with EVI1 overexpression in AML. The gene discussed is AKT1; the disease is acute myeloid leukemia.